

Publication of a paper describing a phase 2 study of cancer vaccine OCV-C01
in patients with biliary tract cancer

An article that described a phase 2 investigator-sponsored study of cancer vaccination therapy in patients with advanced biliary tract cancer (BTC) who had unresectable tumors and were refractory to standard chemotherapy has been published in *Anticancer Research*, by a research group of Dr. Tani (Professor Emeritus of Kyushu University , Project Professor at Institute for Quantitative Biosciences, The University of Tokyo). Peptide vaccines used in this study are proprietary peptides of OncoTherapy Science.

OCV-C01 is an HLA-A*24:02–restricted three-peptide cancer vaccine. In this paper, they reported the efficacy and safety of OCV-C01 for patients with advanced BTC refractory to standard chemotherapy in this exploratory study. Four out of six patients exhibited vaccine-specific T-cell responses, suggesting the association between vaccine-specific T-cell responses and longer overall survival in patients treated with OCV-C01.

The paper has been published online in *Anticancer Research*.

<https://ar.iarjournals.org/content/41/3/1485>

ELISPOT and TCR repertoire analysis were performed by OncoTherapy. OncoTherapy has transferred the operation of the tumor immunology department, which carried out this analysis to a consolidated subsidiary company, Cancer Precision Medicine, Inc.